Faculty

Daniel Rosas

Chief Fellow. Hematology Oncology

Memorial Cancer Institute

Dr. Daniel Rosas is a Hematology–Oncology fellow physician and Chief Fellow at Memorial Cancer Institute. He earned his medical degree from CES University in Medellín, Colombia, and completed internal medicine residency training at the University of Texas Health Science Center at San Antonio. He is currently pursuing advanced subspecialty training in both malignant hematology and solid tumor oncology, with a particular focus on thoracic oncology. Dr. Rosas is committed to delivering evidence-based, compassionate care and is especially passionate about patient education and empowerment. He emphasizes open, transparent communication, shared decision-making, and clear explanation of complex treatment options so that patients and families can participate meaningfully in care planning. His goal is to improve outcomes while supporting quality of life throughout the cancer journey.

2026 Sessions

General Session

Treatment After Progression on Chemoimmunotherapy in Lung Cancer: Continuing Standard Cytotoxic Therapy vs Transitioning to Alternative Approaches

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line...

Moderator
- Edward Garon, MD, MS
- Corey Langer, MD, FACP
Presenter
- Luis Raez, MD, FASCO
- Daniel Rosas, MD

Lung Cancers

2:55

3:15 PM

Continuing Standard Cytotoxic Therapy

Presenter
- Luis Raez, MD, FASCO

Continuing Standard Cytotoxic Therapy

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting.

This session will focus on the role of continuing standard cytotoxic therapy for patients with lung cancer who experience disease progression after frontline chemoimmunotherapy. Faculty will review evidence supporting commonly used second-line chemotherapy options, including expected efficacy and toxicity profiles. Learners will gain perspective on when traditional cytotoxic approaches remain an appropriate and effective strategy after chemoimmunotherapy failure.

Presenter

Sunday, March 15 2:55–3:15 PM

Room Royal Ballroom 2

Lung Cancers

Faculty

Luis Raez

MD, FASCO

Chief Scientific Officer & Medical Director

Memorial Cancer Institute/Florida Atlantic University

Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021.
He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia.
Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the "Miami Best of ASCO" since 2014, Chair and Founder of the "Miami Cancer Meeting (MCM)" since 2002, Co-Chairman at the "Puerto Rico Fall Cancer Symposia (FCS)" since 2010.
He is American Board Certified in: Internal Medicine and Medical Oncology.
He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO.

3:15

3:35 PM

Transitioning to Alternative Approaches

Presenter
- Daniel Rosas, MD

Transitioning to Alternative Approaches

Examine strategies for transitioning to alternative approaches beyond standard cytotoxic therapy in patients with progressive lung cancer. Speakers will review emerging treatment options, including targeted therapies, antibody-drug conjugates, novel immunotherapy strategies, and clinical trial opportunities. The discussion will address biomarker-driven decision-making, safety considerations, and patient selection, giving participants insight into how innovative therapeutic approaches may improve outcomes after chemoimmunotherapy failure.